Hannah L. Kenny, MD, and Joseph M. Curry, MD, on BCC of the Head and Neck: Neoadjuvant Cemiplimab

June 08, 2026

Hannah L. Kenny, MD, and Joseph M. Curry, MD, both of Thomas Jefferson University Hospital, discuss results of a phase II trial of neoadjuvant cemiplimab-rwlc in patients with hedgehog inhibitor–naive basal cell carcinoma (BCC) of the head and neck (Abstract 9515). 

Related Content